Exact Mass: 444.2557
Exact Mass Matches: 444.2557
Found 500 metabolites which its exact mass value is equals to given mass value 444.2557
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Bufotalin
Bufotalin is a steroid lactone. It is functionally related to a bufanolide. Bufotalin is a natural product found in Bufo gargarizans, Duttaphrynus melanostictus Bufotalin is a cardiotoxic bufanolide steroid, cardiac glycoside analogue, secreted by a number of toad species.[2][3] Bufotalin can be extracted from the skin parotoid glands of several types of toad. Rhinella marina (Cane toad), Rhaebo guttatus (Smooth-sided toad), Bufo melanostictus (Asian toad), and Bufo bufo (common European toad) are sources of bufotalin. Traditional medicine Bufotalin is part of Ch'an Su, a traditional Chinese medicine used for cancer. It is also known as Venenum Bufonis or senso (Japanese).[5] Toxicity Specifically, in cats the lethal median dose is 0.13 mg/kg.[1] and in dogs is 0.36 mg/kg (intravenous).[6] Knowing this it is advisable to monitor those functions continuously using an EKG. As there is no antidote against bufotalin all occurring symptoms need to be treated separately or if possible in combination with others. To increase the clearance theoretically, due to the similarities with digitoxin, cholestyramine, a bile salt, might help.[6] Recent animal studies have shown that taurine restores cardiac functions.[7] Symptomatic measures include lignocaine, atropine and phenytoin for cardiac toxicity and intravenous potassium compounds to correct hyperkalaemia from its effect on the Na+/K+ ATPase pump.[6] Pharmacology and mechanism of action After a single intravenous injection, bufotalin gets quickly distributed and eliminated from the blood plasma with a half-time of 28.6 minutes and a MRT of 14.7 min. After 30 minutes after an administration of bufotalin, the concentrations within the brain and lungs are significantly higher than those in blood and other tissues.[8] It also increases cancer cell's susceptibility to apoptosis via TNF-α signalling by the BH3 interacting domain death agonist and STAT proteins.[9] Bufotalin induces apoptosis in vitro in human hepatocellular carcinoma Hep 3B cells and might involve caspases and apoptosis inducing factor (AIF).[10] The use of bufotalin as a cancer treating compound is still in the experimental phase. It also arrests cell cycle at G(2)/M, by up- and down- regulation of several enzymes. Bufotalin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=471-95-4 (retrieved 2024-06-29) (CAS RN: 471-95-4). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation[1][2]. Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation[1][2].
sn-3-O-(geranylgeranyl)glycerol 1-phosphate
Antibiotic GR 95647X
Antibiotic GR 95647X is a constituent of Eucalyptus globulus (Tasmanian blue gum). Constituent of Eucalyptus globulus (Tasmanian blue gum).
MG(6 keto-PGF1alpha/0:0/0:0)
MG(6 keto-PGF1alpha/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(TXB2/0:0/0:0)
MG(TXB2/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/6 keto-PGF1alpha/0:0)
MG(0:0/6 keto-PGF1alpha/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/TXB2/0:0)
MG(0:0/TXB2/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
12-amino-6,9-di-sec-butyl-15-methoxy-4,7,10-triaza-bicyclo[12.3.1]octadeca-1(18),2,14,16-tetraene-5,8,11-trione
geranyl-1-O-alpha-L-arabinofuranosyl-(1->6)-beta-D-glucopyranoside
1-[O-2-(2-methyldecanoyl)] murrangatin|paniculacin
4-Hydroxy-2-[13-(3,4-methylenedioxyphenyl)tridecanoyl]cyclohexane-1,3-dione
2-[13-(1,3-Benzodioxole-5-yl)tridecanoyl]-3,6-dihydroxy-2-cyclohexene-1-one
(1S)-O4-(4-methyl-3-methylamino-beta-L-3-deoxy-arabinopyranosyl)-O6-(6-methyl-2-oxa-5-aza-bicyclo[2.2.2]oct-5-en-3-yl)-2-deoxy-streptamine|Gentamicin I-1
espinasanolide-(angelate) methyl ester|espinasanolide- methyl ester
Dicadalenol|rel-1beta,7-Dihydroxy-2betaH-1,2,3,4-tetrahydro-14,8,2(O),7-dicadalenol
Ala Asn Ile Lys
Ala Ala Gln Arg
Ala Ala Arg Gln
Ala Glu Ile Ile
Ala Glu Ile Leu
Ala Glu Leu Ile
Ala Glu Leu Leu
Ala Ile Glu Ile
Ala Ile Glu Leu
Ala Ile Ile Glu
Ala Ile Lys Asn
Ala Ile Leu Glu
Ala Ile Asn Lys
Ala Lys Ile Asn
Ala Lys Leu Asn
Ala Lys Asn Ile
Ala Lys Asn Leu
Ala Lys Gln Val
Ala Lys Val Gln
Ala Leu Glu Ile
Ala Leu Glu Leu
Ala Leu Ile Glu
Ala Leu Lys Asn
Ala Leu Leu Glu
Ala Leu Asn Lys
Ala Asn Lys Ile
Ala Asn Lys Leu
Ala Asn Leu Lys
Ala Gln Ala Arg
Ala Gln Lys Val
Ala Gln Arg Ala
Ala Gln Val Lys
Ala Arg Ala Gln
Ala Arg Gln Ala
Ala Val Lys Gln
Ala Val Gln Lys
Cys Ile Ile Pro
Cys Ile Leu Pro
Cys Ile Pro Ile
Cys Ile Pro Leu
Cys Leu Ile Pro
Cys Leu Leu Pro
Cys Leu Pro Ile
Cys Leu Pro Leu
Cys Pro Ile Ile
Cys Pro Ile Leu
Cys Pro Leu Ile
Cys Pro Leu Leu
Asp Ile Val Val
Asp Leu Val Val
Asp Val Ile Val
Asp Val Leu Val
Asp Val Val Ile
Asp Val Val Leu
Glu Ala Ile Ile
Glu Ala Ile Leu
Glu Ala Leu Ile
Glu Ala Leu Leu
Glu Ile Ala Ile
Glu Ile Ala Leu
Glu Ile Ile Ala
Glu Ile Leu Ala
Glu Leu Ala Ile
Glu Leu Ala Leu
Glu Leu Ile Ala
Glu Leu Leu Ala
Glu Val Val Val
Gly Gly Arg Arg
Gly Ile Lys Gln
Gly Ile Gln Lys
Gly Lys Ile Gln
Gly Lys Leu Gln
Gly Lys Gln Ile
Gly Lys Gln Leu
Gly Leu Lys Gln
Gly Leu Gln Lys
Gly Asn Arg Val
Gly Asn Val Arg
Gly Gln Ile Lys
Gly Gln Lys Ile
Gly Gln Lys Leu
Gly Gln Leu Lys
Gly Arg Gly Arg
Gly Arg Asn Val
Gly Arg Arg Gly
Gly Arg Val Asn
Gly Val Asn Arg
Gly Val Arg Asn
Ile Ala Glu Ile
Ile Ala Glu Leu
Ile Ala Ile Glu
Ile Ala Lys Asn
Ile Ala Leu Glu
Ile Ala Asn Lys
Ile Cys Ile Pro
Ile Cys Leu Pro
Ile Cys Pro Ile
Ile Cys Pro Leu
Ile Asp Val Val
Ile Glu Ala Ile
Ile Glu Ala Leu
Ile Glu Ile Ala
Ile Glu Leu Ala
Ile Gly Lys Gln
Ile Gly Gln Lys
Ile Ile Ala Glu
Ile Ile Cys Pro
Ile Ile Glu Ala
Ile Ile Pro Cys
Ile Lys Ala Asn
Ile Lys Gly Gln
Ile Lys Asn Ala
Ile Lys Gln Gly
Ile Leu Ala Glu
Ile Leu Cys Pro
Ile Leu Glu Ala
Ile Leu Pro Cys
Ile Asn Ala Lys
Ile Asn Lys Ala
Ile Pro Cys Ile
Ile Pro Cys Leu
Ile Pro Ile Cys
Ile Pro Leu Cys
Ile Gln Gly Lys
Ile Gln Lys Gly
Ile Val Asp Val
Ile Val Val Asp
Lys Ala Ile Asn
Lys Ala Leu Asn
Lys Ala Asn Ile
Lys Ala Asn Leu
Lys Ala Gln Val
Lys Ala Val Gln
Lys Gly Ile Gln
Lys Gly Leu Gln
Lys Gly Gln Ile
Lys Gly Gln Leu
Lys Ile Ala Asn
Lys Ile Gly Gln
Lys Ile Asn Ala
Lys Ile Gln Gly
Lys Leu Ala Asn
Lys Leu Gly Gln
Lys Leu Asn Ala
Lys Leu Gln Gly
Lys Asn Ala Ile
Lys Asn Ala Leu
Lys Asn Ile Ala
Lys Asn Leu Ala
Lys Gln Ala Val
Lys Gln Gly Ile
Lys Gln Gly Leu
Lys Gln Ile Gly
Lys Gln Leu Gly
Lys Gln Val Ala
Lys Val Ala Gln
Lys Val Gln Ala
Leu Ala Glu Ile
Leu Ala Glu Leu
Leu Ala Ile Glu
Leu Ala Lys Asn
Leu Ala Leu Glu
Leu Ala Asn Lys
Leu Cys Ile Pro
Leu Cys Leu Pro
Leu Cys Pro Ile
Leu Cys Pro Leu
Leu Asp Val Val
Leu Glu Ala Ile
Leu Glu Ala Leu
Leu Glu Ile Ala
Leu Glu Leu Ala
Leu Gly Lys Gln
Leu Gly Gln Lys
Leu Ile Ala Glu
Leu Ile Cys Pro
Leu Ile Glu Ala
Leu Ile Pro Cys
Leu Lys Ala Asn
Leu Lys Gly Gln
Leu Lys Asn Ala
Leu Lys Gln Gly
Leu Leu Ala Glu
Leu Leu Cys Pro
Leu Leu Glu Ala
Leu Leu Pro Cys
Leu Asn Ala Lys
Leu Asn Lys Ala
Leu Pro Cys Ile
Leu Pro Cys Leu
Leu Pro Ile Cys
Leu Pro Leu Cys
Leu Gln Gly Lys
Leu Gln Lys Gly
Leu Val Asp Val
Leu Val Val Asp
Met Pro Val Val
Met Val Pro Val
Met Val Val Pro
Asn Ala Ile Lys
Asn Ala Lys Ile
Asn Ala Lys Leu
Asn Ala Leu Lys
Asn Gly Arg Val
Asn Gly Val Arg
Asn Ile Ala Lys
Asn Ile Lys Ala
Asn Lys Ala Ile
Asn Lys Ala Leu
Asn Lys Ile Ala
Asn Lys Leu Ala
Asn Leu Ala Lys
Asn Leu Lys Ala
Asn Arg Gly Val
Asn Arg Val Gly
Asn Val Gly Arg
Asn Val Arg Gly
Pro Cys Ile Ile
Pro Cys Ile Leu
Pro Cys Leu Ile
Pro Cys Leu Leu
Pro Ile Cys Ile
Pro Ile Cys Leu
Pro Ile Ile Cys
Pro Ile Leu Cys
Pro Leu Cys Ile
Pro Leu Cys Leu
Pro Leu Ile Cys
Pro Leu Leu Cys
Pro Met Val Val
Pro Val Met Val
Pro Val Val Met
Gln Ala Ala Arg
Gln Ala Lys Val
Gln Ala Arg Ala
Gln Ala Val Lys
Gln Gly Ile Lys
Gln Gly Lys Ile
Gln Gly Lys Leu
Gln Gly Leu Lys
Gln Ile Gly Lys
Gln Ile Lys Gly
Gln Lys Ala Val
Gln Lys Gly Ile
Gln Lys Gly Leu
Gln Lys Ile Gly
Gln Lys Leu Gly
Gln Lys Val Ala
Gln Leu Gly Lys
Gln Leu Lys Gly
Gln Arg Ala Ala
Gln Val Ala Lys
Gln Val Lys Ala
Arg Ala Ala Gln
Arg Ala Gln Ala
Arg Gly Gly Arg
Arg Gly Asn Val
Arg Gly Arg Gly
Arg Gly Val Asn
Arg Asn Gly Val
Arg Asn Val Gly
Arg Gln Ala Ala
Arg Arg Gly Gly
Arg Val Gly Asn
Arg Val Asn Gly
Val Ala Lys Gln
Val Ala Gln Lys
Val Asp Ile Val
Val Asp Leu Val
Val Asp Val Ile
Val Asp Val Leu
Val Glu Val Val
Val Gly Asn Arg
Val Gly Arg Asn
Val Ile Asp Val
Val Ile Val Asp
Val Lys Ala Gln
Val Lys Gln Ala
Val Leu Asp Val
Val Leu Val Asp
Val Met Pro Val
Val Met Val Pro
Val Asn Gly Arg
Val Asn Arg Gly
Val Pro Met Val
Val Pro Val Met
Val Gln Ala Lys
Val Gln Lys Ala
Val Arg Gly Asn
Val Arg Asn Gly
Val Val Asp Ile
Val Val Asp Leu
Val Val Glu Val
Val Val Ile Asp
Val Val Leu Asp
Val Val Met Pro
Val Val Pro Met
Val Val Val Glu
AL 8810 isopropyl ester
LPA O-20:4
benzyl N-[1-(1-hydroxy-1-phenylpropan-2-yl)piperidin-4-yl]-N-phenylcarbamate
[4-[[4-(diethylamino)phenyl]phenylmethylene]-2,5-cyclohexadien-1-ylidene]diethylammonium acetate
N-(3-Amino-4-chlorophenyl)-4-(2,4-di-tert-pentylphenoxy)butanamide
Lovastatin hydroxy acid sodium
Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a Ki of 0.6 nM[1].
1-[2-[4-Hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]-α,α-diphenyl-
2-Chloro-1,3-bis(2,6-diisopropylphenyl)-1,3,2-diazaphospholidine
TETRABUTYLPHOSPHONIUM O,O-DIETHYL PHOSPHORODITHIOATE
1-Azetidinepentanamide, 3-(3-hydroxyphenoxy)-delta,delta-dimethyl-alpha,alpha-diphenyl-
Benzamide, N-(4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butyl)-2-(2-(fluoro-18F)ethoxy)-5-methyl-
(2E,4E,6E,8E,10E,12E,14E,16E,18E,20E,22E)-2,6,10,15,19,23-hexamethyl-24-oxotetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaenoic acid
3-[(2R)-3,5-dioxo-4-[(2E.4S,6S,8E,10E,12E)-4,6,12-trimethyltetradeca-2,8,10,12-tetraenoyl]pyrrolidin-2-yl]-2-hydroxy-2-methylpropanoate
[(6S)-17-(3,5-dihydroxyphenyl)heptadecan-6-yl] hydrogen sulate
Xyloketal E
A xyloketal with formula C26H36O6. It was initially isolated from the mangrove fungus Xylaria sp. from the South China sea coast.
1-[[3-(4-Fluorophenyl)-1-(4-methylphenyl)-4-pyrazolyl]methyl]-4-[(1-methyl-2-imidazolyl)methyl]piperazine
asnovolin K
A meroterpenoid with formula C26H36O6 isolated from the fungus Aspergillus novofumigatus. It is an intermediate produced in the biosynthetic pathway leading to the synthesis of novofumigatonin.
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
[(2S,3R)-6-[(2-methoxyphenyl)methyl]-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
1-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
N-[(5S,6R,9R)-8-ethyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-isoxazolecarboxamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(2-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(2-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-4-oxanecarboxamide
1-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
1-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-propylurea
N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(2-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(2-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(2-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]-4-oxanecarboxamide
6-(Isobutyldimethylsilyl)-2-(pentamethyldisilanyl)-5-(trimethylsilyl)naphthalene
1-[2,4-dihydroxy-6-(2-oxopropyl)phenyl]-11-hydroxy-2,4,6,8,10-pentamethyldodeca-6,8-diene-3,5-dione
8a-hydroxy-3,4a,5-trimethyl-9-[(2-methylbut-2-enoyl)oxy]-4h,5h,6h,7h,8h,9h-naphtho[2,3-b]furan-4-yl 3-methylpent-2-enoate
(2s)-2-{[(2s)-1-hydroxy-2-[(1-hydroxyethylidene)amino]-3-[(1e,4r)-4-(methylamino)cyclohex-2-en-1-ylidene]propylidene]amino}-3-[(1e,4r)-4-[(1-hydroxyethylidene)amino]cyclohex-2-en-1-ylidene]propanoic acid
methyl 14-acetyl-14-hydroxy-2,6,6,10,13-pentamethyl-16-methylidene-7,15-dioxotetracyclo[11.2.1.0²,¹¹.0⁵,¹⁰]hexadecane-1-carboxylate
(3r,4s,5s,6r,7r,8r)-5,6,7-trihydroxy-2,2,4,6,8-pentamethyl-9-oxooxonan-3-yl (2e,4r)-4-hydroxydec-2-enoate
2-({1-hydroxy-2-[(1-hydroxyethylidene)amino]-3-[(1z)-4-(methylamino)cyclohex-2-en-1-ylidene]propylidene}amino)-3-[(1e)-4-[(1-hydroxyethylidene)amino]cyclohex-2-en-1-ylidene]propanoic acid
10-[4-(acetyloxy)-5-(2-methylprop-1-en-1-yl)-2-oxooxolan-3-ylidene]-3,7-dimethyldeca-2,6-dien-1-yl 2-methylprop-2-enoate
[(1r,6s)-6-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,5-dioxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl (3s)-3-hydroxybutanoate
5-{10,11-dihydroxy-2,6,15,19-tetramethyl-3,8-dioxatetracyclo[9.8.0.0²,⁷.0¹²,¹⁷]nonadeca-14,18-dien-9-yl}penta-2,4-dienoic acid
2-[11-(2-methoxypropan-2-yl)-8-methyl-3-oxo-5-(2-oxopropyl)-4-oxatricyclo[6.3.1.0²,⁶]dodec-2(6)-en-7-yl]ethenyl 3-methylbut-2-enoate
(3r,8as)-5-propyl-3-(tetradecyloxy)-1h,8h,8ah-3λ⁵-furo[3,4-e][1,3,2]dioxaphosphepine-3,6-dione
(3r,8ar)-3-(hexadecyloxy)-5-methyl-1h,8h,8ah-3λ⁵-furo[3,4-e][1,3,2]dioxaphosphepine-3,6-dione
2-[2,7-dihydroxy-3-methyl-5-(2-oxopropyl)-3,4-dihydro-1-benzopyran-2-yl]-9-hydroxy-4,6,8-trimethyldeca-4,6-dien-3-one
3-(hexadecyloxy)-5-methyl-1h,8h,8ah-3λ⁵-furo[3,4-e][1,3,2]dioxaphosphepine-3,6-dione
15-o-methyl-18-oxoneovibsanin f
{"Ingredient_id": "HBIN001711","Ingredient_name": "15-o-methyl-18-oxoneovibsanin f","Alias": "NA","Ingredient_formula": "C26H36O6","Ingredient_Smile": "CC(=CC(=O)OC=CC1C2=C(C3CC1(CCC3C(C)(C)OC)C)C(=O)OC2CC(=O)C)C","Ingredient_weight": "444.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "14640","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11351274","DrugBank_id": "NA"}